An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.

[1]  P. Mwinzi,et al.  CD23-Bound IgE Augments and Dominates Recall Responses through Human Naive B Cells , 2010, The Journal of Immunology.

[2]  Hwan-You Chang,et al.  Unique Epitopes on CεmX in IgE–B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells , 2010, The Journal of Immunology.

[3]  R. Katz,et al.  Effects of omalizumab in patients with food allergy. , 2010, Allergy and asthma proceedings.

[4]  J. Bousquet,et al.  The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. , 2009, Respiratory medicine.

[5]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[6]  J. Byrd,et al.  Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. , 2008, Blood.

[7]  D. Conrad,et al.  CD23: An overlooked regulator of allergic disease , 2007, Current allergy and asthma reports.

[8]  J. Byrd,et al.  Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia , 2007, Clinical Cancer Research.

[9]  P. Lipsky,et al.  The Low Affinity IgE Receptor (CD23) Is Cleaved by the Metalloproteinase ADAM10* , 2007, Journal of Biological Chemistry.

[10]  C. Hsu,et al.  Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. , 2007, Advances in immunology.

[11]  Anne E. Shelburne,et al.  In vivo murine CD23 destabilization enhances CD23 shedding and IgE synthesis. , 2006, Cellular immunology.

[12]  T. Chang,et al.  Anti-IgE as a mast cell-stabilizing therapeutic agent. , 2006, The Journal of allergy and clinical immunology.

[13]  B. Lanier.  Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. , 2006, Allergy and asthma proceedings.

[14]  M. Spellman,et al.  Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. , 2005, The Journal of allergy and clinical immunology.

[15]  Rebecca L. Beavil,et al.  The structure of human CD23 and its interactions with IgE and CD21 , 2005, The Journal of experimental medicine.

[16]  J. Bousquet,et al.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.

[17]  Rosalind Wright,et al.  Population disparities in asthma. , 2005, Annual review of public health.

[18]  G. B. Wisdom,et al.  Conjugation of antibodies to horseradish peroxidase. , 2005, Methods in molecular biology.

[19]  A. Togias,et al.  Omalizumab-induced reductions in mast cell FcεRI expression and function , 2004 .

[20]  T. Casale,et al.  Rationale for new treatments aimed at IgE immunomodulation. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  S. Salminen,et al.  The allergy epidemic extends beyond the past few decades , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  H. Towbin,et al.  Can anti-IgE be used to treat allergy? , 2004, Springer Seminars in Immunopathology.

[23]  W. Busse,et al.  Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. , 2003, The Journal of allergy and clinical immunology.

[24]  W. Lumry,et al.  Omalizumab is effective in the long-term control of severe allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[25]  H. Niiro,et al.  Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.

[26]  M. Brigham-Burke,et al.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti‐interleukin‐4 antibody with therapeutic potential in asthma , 2002, Clinical and experimental immunology.

[27]  M. Reff,et al.  Anti-CD23 monoclonal antibody inhibits germline Cε transcription in B cells , 2002 .

[28]  P. Brams,et al.  In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. , 2000, International journal of immunopharmacology.

[29]  T. Chang.  The pharmacological basis of anti-IgE therapy , 2000, Nature Biotechnology.

[30]  Salvi Ss,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. , 1999 .

[31]  R. Bush,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. , 1999, The New England journal of medicine.

[32]  J. Kinet,et al.  High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. , 1996, Journal of immunology.

[33]  A. Beavil,et al.  Alpha-helical coiled-coil stalks in the low-affinity receptor for IgE (Fc epsilon RII/CD23) and related C-type lectins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Mermod,et al.  Inhibition of human interleukin 4‐induced IgE synthesis by a subset of anti‐CD23/FcϵRII monoclonal antibodies , 1990 .

[35]  D. Conrad.  FcεRII/CD23: The Low Affinity Receptor for IgE , 1990 .